A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone

Trial Profile

A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Pracinostat (Primary) ; Azacitidine; Azacitidine; Decitabine; Decitabine
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Sponsors MEI Pharma
  • Most Recent Events

    • 01 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 15 Apr 2016 Planned End Date changed from 1 Aug 2015 to 1 Dec 2016.
    • 15 Apr 2016 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top